Building upon a successful end-of-Phase 2 meeting, received FDA "Study May Proceed" letter for pivotal Phase 3 trial of amezalpat (TPST-1120) combination therapy to treat first-line HCCAnnounced agree ...

Junaluska Sanitary District has been awarded $9.5 million from the N.C. Drinking Water State Revolving Fund to upgrade the ...

The agreement builds on a clinical collaboration between the companies pursuant to which amezalpat was combined with ...

HCC risk prediction may be poorly reported and biased for individuals ... The final models were presented as an equation (n=2), a point-based model (n=2), a nomogram (n=2), and a web-based tool (n=1).

Portal vein thrombosis (PVT) is a challenging complication in liver cirrhosis, with no currently available sensitive ...

Symptoms can include upper abdominal pain, yellow discolouration of the skin and general widespread weakness in the body.

Hepatocellular carcinoma (HCC) is a significant global health concern, particularly in regions like the Asia-Pacific, where chronic viral hepatitis ...

Wednesday, council was asked to approve a certificate of appropriateness related to the 141-guest room "Tempo By Hilton" hotel planned for 14-36 W. Third St.

Why one of Houston Community College’s first students pursuing an artificial intelligence bachelor’s degree, calls the ...

"We look forward to further advancing the anti-GPC3 in vivo CAR-M therapy for HCC patients and continuing our collaboration ... audiobook, ebook and website that reflects on the radical transformation ...

REDWOOD CITY, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus or the Company, Nasdaq: CHRS), today reported financial results for the quarter ended September 30, 2024 and ...